Charles M. Perou, PhD, will receive the Association of American Cancer Institutes Distinguished Scientist Award on October 1, during the 2018 AACI/CCAF Annual Meeting, in Chicago. The award recognizes Dr. Perou’s research in the field of precision medicine and in the characterization of the diversity of human tumors.
Researchers at Memorial Sloan Kettering (MSK) report that firefighters at the World Trade Center (WTC) scene in September 2001 were nearly twice as likely as the general population to have a multiple myeloma precursor condition called monoclonal gammopathy of undetermined significance (MGUS).
The ‘Splash Away Cancer!’ event will take place Saturday, May 19. The swimming fundraiser supports cancer research and patient care programs at The University of New Mexico Comprehensive Cancer Center.
The Florida Department of Health’s James and Esther King Biomedical Research Program has armed Moffitt Cancer Center, University of Florida (UF) Health Cancer Center – Gainesville, Sylvester Comprehensive Cancer Center at the University of Miami and numerous collaborating centers with $1.36 million to address cancer disparities and improve outcomes and care for individuals affected by pancreatic cancer.
TAMPA, Fla. – Cancer patients are commonly treated with the maximum dose they are able to withstand that does not cause too many toxic side effects. However, many patients become resistant to these treatments and develop cancer recurrence. Researchers at Moffitt Cancer Center are using mathematical modeling based on evolutionary principles to show that adaptive drug treatments based on tumor responses to prior treatment are more effective than maximum-tolerated dose approaches for certain tumor situations.
The majority of patients with diffuse large B cell lymphoma (DLBCL) can be treated effectively. However, people whose disease recurs face a shortage of good options, especially because the disease is driven by a complicated mix of genetic alterations. Genomic analysis by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard now offers a better framework for understanding the disease’s many forms, which will help to predict individual patient outcomes and guide personalized treatment.
Bone marrow biopsies are the gold standard for diagnosing and monitoring the progression of multiple myeloma, but these procedures are far too invasive to perform at every patient visit. Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, however, have shown that two ways to measure multiple myeloma DNA in blood samples provide highly detailed sets of genetic information that agree well not just with each other but with results from bone marrow tests.
CU researchers mine data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers, showing genetic alterations, and "high mutation burden" that is an FDA-approved marker for immunotherapy.
If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
The NCCN Foundation® announces Chinese, Czech, German, Italian, and Spanish translations of patient-focused booklets designed to help people with cancer make shared decisions about their treatment.
Organizers of the second annual Lobo Cancer Challenge have opened registration. The event will take place Sept. 8 at Dreamstyle Stadium. In addition to the 100-, 50- and 25-mile bike rides, the organizing team is adding a 5K run/walk this year. Proceeds benefit The University of New Mexico Comprehensive Cancer Center.
Representatives of the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) visited federal legislators Tuesday to express their gratitude for a bipartisan spending package for fiscal year 2018 that prioritized funding for NIH, NCI, and the FDA.
A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable form of the disease, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
Investigators at Rutgers Cancer Institute have discovered that some mutations detected in comprehensive, clinical genome sequencing of patients with solid tumors do not originate from cancer cells, but arise from mutated hematopoietic cells that infiltrate the tumor microenvironment. The findings, they say, have direct implications for cancer patients, specifically in accurately interpreting their molecular testing results and ensuring that treatment is focused on somatic tumor-specific mutations.
Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary diagnosis, and even though chemotherapy can be effective as standard-of-care, many patients become resistant to treatment. A team at The University of Texas MD Anderson led a study which may explain how resistance evolves over time, and potentially which patients could benefit from chemotherapy.
A new University of Kansas research effort featured in the current edition of Integrative Biology has resulted in a low-cost, reliable blood test that uses a small plastic chip about the size of a credit card that can deliver the same diagnostic information as a bone biopsy — but using a simple blood draw instead.
TAMPA, Fla. – Patients with advanced or metastatic melanoma have been able to live longer cancer-free lives because of several new therapies approved over the last decade, such as BRAF and MEK inhibitors. However, despite the success of these targeted agents, most patients eventually develop drug resistance and their cancer regrows.
Roswell Park Comprehensive Cancer Center researchers have identified epigenetic differences in the breast cancer tumors of African-American women and women of European descent, shedding light on one mechanism by which race may influence the way breast cancer develops.
Roswell Park Comprehensive Cancer Center researchers have once again identified a link between physical inactivity and an increased risk of mortality among cancer patients, emphasizing the importance of regular exercise as therapy for cancer patients both during and after treatment.
A study published in JNCCN estimates costs for people age 18 and up, ranks the price tags of the top four cancer types, and highlights potential cost-saving benefits of prevention and screening.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right